IP Library Granted Patent US 10,500,157
Granted Patent B2
US 10,500,157 · App. 16/019,704 · Granted Dec 10, 2019

Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory T cell phenotype

Inventor: Tarek M. Fahmy (New Haven, CT)
Assignee: Yale University
A61K9/127A61K9/0019A61K9/1271A61K9/1273A61K9/1277A61K9/5153A61K31/343A61K38/1841A61K38/2013A61K47/24A61K47/40A61K47/58A61K47/6849A61K47/6937A61K47/6951B82Y5/00C07K16/2812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,500,157
App. No.
16/019,704
Granted
Dec 10, 2019
Kind
B2
Abstract

Compositions for delivery of growth factors needed for stable Tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced CD4 Treg population (e.g., Foxp3+ Treg) in vivo or ex vivo. The compositions generally include delivery vehicles including TGF-β and IL-2. Delivery vehicles include, for example, polymeric particles, silica particles, liposomes, or multilamellar vesicles. The TGF-β and IL-2 are typically co-loaded into, attached to the surface of, and/or enclosed within the delivery vehicle into the same particle for simultaneous co-delivery to cells such as T cells. Preferably the delivery vehicles are targeted to CD4. The compositions and cells treated therewith can be used in various methods of treating, for example, inflammation, inflammatory and autoimmune diseases and disorders, and inducing or maintaining tolerance including graft and transplant tolerance.

Claims (1)

1. A method of increasing donor specific Treg comprising treating isolated cells ex vivo with a composition comprising CD4-targeted nanoparticles loaded with a combination of TGF-β and IL-2.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 31, 2025
From: YALE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070675/0792 →
LICENSE Recorded May 7, 2020
From: YALE UNIVERSITY
To: MODULATE THERAPEUTICS INC
Reel/Frame 052598/0264 →
LICENSE Recorded May 7, 2020
From: YALE UNIVERSITY
To: IMMUNOVA LLC
Reel/Frame 052598/0330 →
Continuity (6)
Continuation 15155055 · May 15, 2016
Continuation In Part 14394161
Provisional Application 61623486 · Apr 12, 2012
Provisional Application 61747624 · Dec 31, 2012
Provisional Application 61747614 · Dec 31, 2012
Related Publication 20180369333A1 · Dec 27, 2018